ESPR
NASDAQ
US
Esperion Therapeutics, Inc. - Common Stock
$2.61
▲ +$0.00
(+0.00%)
Vol 5.8M
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$884.5M
ROE
-59.5%
Margin
-34.8%
D/E
0.00
Beta
1.10
52W
$1–$4
Wall Street Consensus
14 analysts · Apr 20263
Strong Buy
8
Buy
2
Hold
1
Sell
0
Strong Sell
78.6%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 25.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.25 | $0.22 | $-0.03 |
| Sep 2025 | $-0.06 | $-0.16 | $-0.10 |
| Jun 2025 | $-0.15 | $-0.02 | +$0.13 |
| Mar 2025 | $-0.16 | $-0.21 | $-0.05 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $69.1M | $65.0M | $82.4M | $87.3M | $168.4M |
| Net Income | — | -$21.3M | -$40.5M | -$12.7M | -$31.3M | $61.8M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -59.5% | -59.5% | -59.5% | -59.5% | -59.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -15.4% | -38.8% | -38.8% | -38.8% | -34.8% | -34.8% |
| Gross Margin | 65.3% | 61.6% | 61.6% | 61.6% | 58.2% | 58.2% |
| D/E Ratio | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 1.15 | 1.15 | 1.15 | 1.15 | 1.00 | 1.00 |
Key Ratios
ROA (TTM)
-30.7%
P/S (TTM)
2.91
P/B
81.9
EPS (TTM)
$-0.54
CF/Share
$-2.23
Rev Growth 3Y
+61.8%
52W High
$4.13
52W Low
$0.69
$0.69
52-Week Range
$4.13
Financial Health
Free Cash Flow
$45.2M
Net Debt
$84.4M
Cash
$167.9M
Total Debt
$252.2M
As of Dec 31, 2025
How does ESPR compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
ESPR valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
2.9
▼
41%
below
peers
(5.0)
vs Peers
vs Industry
Undervalued
P/B ratio
81.9
▲
3763%
above
peers
(2.1)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
ESPR profitability vs Pharmaceuticals peers
ROE
-59.5%
▼
10%
below
peers
(-54.3%)
vs Peers
vs Industry
In line
Net margin
-34.8%
▲
26%
above
peers
(-47.4%)
vs Peers
vs Industry
Weak
Gross margin
58.2%
▼
15%
below
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
-30.7%
▲
18%
above
peers
(-37.4%)
vs Peers
vs Industry
Below avg
ESPR financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(1.5)
vs Peers
vs Industry
Low debt
Current ratio
1.0
▼
70%
below
peers
(3.4)
vs Peers
vs Industry
Low liquidity
Beta
1.1
▲
17%
above
peers
(0.9)
vs Peers
vs Industry
More volatile
ESPR fundamentals radar
ESPR
Peer median
Industry
ESPR profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ESPR vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
HALLADAY BENJAMIN
Chief Financial Officer · Mar 17
6424 shs
KOENIG SHELDON L
Chief Executive Officer · Mar 17
25578 shs
LOOKER BENJAMIN
Officer · Mar 17
5708 shs
KOENIG SHELDON L
Chief Executive Officer · Mar 13
723760 shs
LOOKER BENJAMIN
Officer · Mar 13
300840 shs
HALLADAY BENJAMIN
Chief Financial Officer · Mar 13
247430 shs
LOOKER BENJAMIN
General Counsel · Jan 20
1689 shs
Last 90 days
Top Holders
Top 5: 23.71%Blackrock Inc.
6.89%
$48.4M
Vanguard Group Inc
5.82%
$41.0M
Two Seas Capital Lp
4.63%
$32.6M
Wasatch Advisors LP
3.68%
$25.9M
Shaw D.E. & Co., Inc.
2.69%
$18.9M
As of Dec 31, 2025